Skip to content
value.today
PAREXEL logo

PAREXEL

PRXLUnlisted company
No market cap data
Compare
World rank
—
no current market cap
Revenue
—
annual
Net income
—
Employees
—

About PAREXEL

Parexel is an American contract research organization. It conducts clinical trials on behalf of its pharmaceutical and biotechnology clients to expedite drug development and clinical trial progress.

Parexel was founded in 1982 by Josef von Rickenbach and organic chemist Anne B. Sayigh initially to advise Japanese and German firms on how to navigate the US Food and Drug Administration (FDA) drug approval process. The firm has grown organically over the years and through 40 acquisitions. Josef von Rickenbach is credited with establishing Parexel's culture and practices based on the principles he experienced as a researcher at Schering-Plough in Lucerne, Switzerland, before leaving the company upon retiring in 2018. In 1990, the firm expanded internationally and established new practice areas. By 1999, it had a staff of 4,500 and 45 offices.

The company was acquired in 2017 by private equity firm Pamplona Capital Management. On July 2, 2021, Parexel announced a merger agreement under which it would be acquired by EQT IX fund and Goldman Sachs for $8.5 billion. EQT and Goldman Sachs completed the acquisition on November 15, 2021.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

PAREXEL timeline

3 events, 1982–2022
  1. 1982
  2. 🏁
    · approximate
    Founded
  3. 2012
  4. •
    Legal Entity Identifier issued
    LEI 549300GCZVUYB6P2OA17 registered.
  5. 2022
  6. ✎
    Renamed Parexel International (Ma) Corporation
    Legal name change recorded in the LEI register.

Events of PAREXEL from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about PAREXEL

Acquisitions and changes
No longer listed: ticker PRXL is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).

Market cap history

Not enough history yet.

Layoffs at PAREXEL#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
3
2019–2019
Latest
3 people
2019-04-16
PAREXEL: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2019···3········3
PAREXEL: latest layoffs
AnnouncedPeopleKindWhereSource
effective 3 peopleClosureWARN noticeSan Diego County, CaliforniaNotice list
CompanyMarket capP/ENet marginRev. growth
PAREXEL🇺🇸————
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Profile updated:
Nov 14, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at PAREXEL? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show PAREXEL's ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about PAREXEL? Suggest a correction